Compare Kinder Morgan Inc (KMI) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Kinder Morgan Inc trades at $33.53 (market cap $74.26B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Kinder Morgan Inc is far larger — about 10.1× Spyre Therapeutics Inc. Common Stock's market cap, and Kinder Morgan Inc pays a 3.54% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 151 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| KMI | SYRE | |
|---|---|---|
Market Cap | $74.26B | $7.35B |
Volume | 12,072,157 | 1,624,631 |
Sector | Energy | Health |
52-Week High | $34.31 | $108.92 |
52-Week Low | $25.84 | $22.18 |
Typical Hold Time | 151 Days | 0 Days |
Enterprise Value | $106.31B | $6.35B |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $33.43, up 1.06% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains solid fundamentals with $16.94B revenue, 19.31% net margin, and a $6B-$7B growth pipeline. Analyst consensus is mixed with 47% buy ratings and a $37.20 price target, while technical indicators show support at $33 and resistance at $34.
KMI offers income investors a compelling dividend yield with growth potential from natural gas infrastructure demand, though elevated debt levels and energy market volatility present risks. The stock's current valuation at 21.57 P/E appears reasonable given earnings growth trajectory and stable fee-based revenue model.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
